Ignite Creation Date:
2025-12-24 @ 9:34 PM
Ignite Modification Date:
2025-12-31 @ 10:21 PM
Study NCT ID:
NCT01273532
Status:
COMPLETED
Last Update Posted:
2012-03-13
First Post:
2011-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-12
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2011-03
Completion Date Type:
ACTUAL
First Submit Date:
2011-01-07
First Submit QC Date:
None
Study First Post Date:
2011-01-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-03-12
Last Update Post Date:
2012-03-13
Last Update Post Date Type:
ESTIMATED